Back to top
more

CureVac (CVAC)

(Real Time Quote from BATS)

$2.87 USD

2.87
176,695

+0.16 (5.90%)

Updated Nov 5, 2024 02:17 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal

by Zacks Equity Research

The phase I/II proof-of-concept study evaluating GSK's herpes simplex virus vaccine candidate, GSK3943104, fails to meet the primary efficacy objective.

CorMedix (CRMD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CorMedix (CRMD) delivered earnings and revenue surprises of 3.85% and 7.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Adherex Technologies (FENC) delivered earnings and revenue surprises of -433.33% and 46.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -9.76% and 24.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Ontrak, Inc. (OTRK) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ontrak (OTRK) delivered earnings and revenue surprises of -90% and 5.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

CureVac N.V. (CVAC) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

CureVac (CVAC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Incyte (INCY) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of -333.33% and 2.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

CureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

CureVac (CVAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac

by Zacks Equity Research

GSK revamps its existing collaboration deal with partner CureVac, converting it from a collaboration deal into a licensing agreement related to mRNA vaccine candidates for COVID-19 and influenza.

Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More

by Zacks Equity Research

GSK and CureVac (CVAC) are in the spotlight following a restructuring of their vaccine agreement.

Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine

by Zacks Equity Research

Moderna (MRNA) expects this funding to help support the development of its mRNA-based pre-pandemic vaccine against the H5 influenza virus, which is responsible for causing avian influenza or bird flu.

Sundeep Ganoria headshot

Vaccine Stocks Rise on Growing Threat of Bird Flu Infections

by Sundeep Ganoria

The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.

Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)

by Zacks Equity Research

CureVac N.V. (CVAC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -15.09% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)

by Zacks Equity Research

The heavy selling pressure might have exhausted for CureVac N.V. (CVAC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Can CureVac N.V. (CVAC) Climb 191.74% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 191.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Company News for Jan 11, 2023

by Zacks Equity Research

Companies In The News Are: SNX, ACI, MSFT, CVAC.

Wall Street Analysts Believe CureVac N.V. (CVAC) Could Rally 139%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 139% upside potential for CureVac N.V. (CVAC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Ekta Bagri headshot

Bet on These 4 Biotech Stocks With Bright Prospects

by Ekta Bagri

New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.

Here's Why CureVac N.V. (CVAC) is Poised for a Turnaround After Losing 20.9% in 4 Weeks

by Zacks Equity Research

CureVac N.V. (CVAC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Wall Street Analysts Predict a 96% Upside in CureVac N.V. (CVAC): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 96.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 53% Upside in CureVac N.V. (CVAC): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 53.3% in CureVac N.V. (CVAC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

CureVac (CVAC) Begins Influenza Shot Dosing in Phase I Study

by Zacks Equity Research

CureVac (CVAC) doses the first patient in a phase I study with investigational influenza vaccine candidate.

Glaxo (GSK), Medicago COVID-19 Jab Effective Against Variants

by Zacks Equity Research

Glaxo (GSK) and Medicago's plant-based vaccine achieves more than 70% efficacy rate against COVID-19 and its major variants.

Glaxo (GSK), SK bioscience's COVID-19 Jab Enters Phase III Study

by Zacks Equity Research

GlaxoSmithKline (GSK) and SK bioscience begin a phase III study on GBP510, the latter's COVID-19 vaccine candidate. The study will compare GBP510 against AstraZeneca's COVID-19 vaccine.

Biotech Stock Roundup: MRNA Vaccine Updates, Other Regulatory News & Collaborations

by Zacks Equity Research

Regulatory and pipeline updates from Moderna (MRNA) and CureVac (CVAC) among others were in focus in the biotech industry over the past week.